Milnacipran hydrochloride - Generic Drug Details

What are the generic sources for milnacipran hydrochloride and what is the scope of patent protection?

Milnacipran hydrochloride is the generic ingredient in two branded drugs marketed by Amneal Pharms, Breckenridge, Hetero Labs Ltd V, and Abbvie, and is included in four NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Milnacipran hydrochloride has thirty-three patent family members in twenty-three countries.

There are twenty-six drug master file entries for milnacipran hydrochloride. Five suppliers are listed for this compound. There are six tentative approvals for this compound.

Summary for milnacipran hydrochloride

International Patents:	33
US Patents:	1
Tradenames:	2
Applicants:	4
NDAs:	4
Drug Master File Entries:	26
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	62
Clinical Trials:	57
Patent Applications:	796
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for milnacipran hydrochloride
What excipients (inactive ingredients) are in milnacipran hydrochloride?	milnacipran hydrochloride excipients list
DailyMed Link:	milnacipran hydrochloride at DailyMed

Recent Clinical Trials for milnacipran hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ain Shams University	NA
Mansoura University	N/A
Yousra Hisham Abdel Fattah	N/A

See all milnacipran hydrochloride clinical trials

Generic filers with tentative approvals for MILNACIPRAN HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		100MG	TABLET;ORAL
		50MG	TABLET;ORAL
		25MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for milnacipran hydrochloride

Drug Class	Serotonin and Norepinephrine Reuptake Inhibitor
Mechanism of Action	Norepinephrine Uptake Inhibitors Serotonin Uptake Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for milnacipran hydrochloride

N06AX	Other antidepressants
N06A	ANTIDEPRESSANTS
N06	PSYCHOANALEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for MILNACIPRAN HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SAVELLA	Tablets	milnacipran hydrochloride	12.5 mg, 25 mg, 50 mg, and 100 mg	022256	8	2013-01-14

US Patents and Regulatory Information for milnacipran hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	SAVELLA	milnacipran hydrochloride	TABLET;ORAL	022256-001	Jan 14, 2009	AB	RX	Yes	No	7,994,220
Hetero Labs Ltd V	MILNACIPRAN HYDROCHLORIDE	milnacipran hydrochloride	TABLET;ORAL	205147-004	Oct 3, 2024		DISCN	No	No
Amneal Pharms	MILNACIPRAN HYDROCHLORIDE	milnacipran hydrochloride	TABLET;ORAL	205081-002	Apr 22, 2016	AB	RX	No	No
Breckenridge	MILNACIPRAN HYDROCHLORIDE	milnacipran hydrochloride	TABLET;ORAL	205071-001	Jan 27, 2016	AB	RX	No	No
Breckenridge	MILNACIPRAN HYDROCHLORIDE	milnacipran hydrochloride	TABLET;ORAL	205071-003	Jan 27, 2016	AB	RX	No	No
Hetero Labs Ltd V	MILNACIPRAN HYDROCHLORIDE	milnacipran hydrochloride	TABLET;ORAL	205147-002	Oct 3, 2024		DISCN	No	No

Expired US Patents for milnacipran hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	SAVELLA	milnacipran hydrochloride	TABLET;ORAL	022256-004	Jan 14, 2009	7,888,342
Abbvie	SAVELLA	milnacipran hydrochloride	TABLET;ORAL	022256-001	Jan 14, 2009	6,602,911
Abbvie	SAVELLA	milnacipran hydrochloride	TABLET;ORAL	022256-004	Jan 14, 2009	6,602,911
Abbvie	SAVELLA	milnacipran hydrochloride	TABLET;ORAL	022256-002	Jan 14, 2009	7,888,342
Abbvie	SAVELLA	milnacipran hydrochloride	TABLET;ORAL	022256-003	Jan 14, 2009	7,888,342
Abbvie	SAVELLA	milnacipran hydrochloride	TABLET;ORAL	022256-004	Jan 14, 2009	6,992,110

International Patents for milnacipran hydrochloride

Country	Patent Number	Title	Estimated Expiration
Norway	20081951
Israel	190284
Georgia, Republic of	P20125595
Ukraine	94721
Russian Federation	2437661
China	101355930

Market Dynamics and Financial Trajectory for Milnacipran Hydrochloride

Last updated: March 12, 2026

What is the current market landscape for Milnacipran Hydrochloride?

Milnacipran Hydrochloride is a serotonin-norepinephrine reuptake inhibitor (SNRI) primarily approved for treating fibromyalgia in the United States. It is marketed under the brand name Savella by Mitsubishi Tanabe Pharma. Globally, its presence is limited, with regulatory approvals primarily in the U.S., Japan, and select European markets.

The drug's market penetration remains modest compared to other SNRI class medications such as duloxetine and milnacipran's closest competitor, venlafaxine. The specialty focus on fibromyalgia, a condition with variable diagnosis rates and complex management, constrains its broader market share.

How does regulatory approval impact market potential?

The U.S. Food and Drug Administration (FDA) approved Milnacipran in 2009 explicitly for fibromyalgia treatment. Japan granted approval in 2010, with some European countries following cautiously, primarily for off-label or investigational use.

Regulatory restrictions influence market access. Absence of approvals for other indications limits revenue streams, especially since off-label use remains limited and generally not reimbursed.

What are the sales figures and revenue trends?

Estimates indicate that annual U.S. sales of Savella peaked around $90 million in 2013. Since then, sales declined due to market saturation, competition from other SNRI drugs, and limited expansion.

Internationally, Milnacipran Hydrochloride’s sales represent less than 10% of global SNRI revenues, accounting for approximately $20 million annually, primarily driven by Japan and select European countries.

Year	U.S. Sales (million USD)	International Sales (million USD)
2013	90	15
2015	55	10
2018	35	8
2020	20	5

Market decline aligns with the expiration of patent exclusivity in multiple jurisdictions, leading to generic competition and price erosion.

What factors influence future growth prospects?

The outlook hinges on several key elements:

• Regulatory developments: Additional approvals for new indications could open revenue channels. Currently, no significant expansion applications are underway.

• Competitive landscape: Many SNRI medications are available as generics, increasing price competition. Duplicates such as duloxetine enjoy broader labeling and insurance coverage.

• Market acceptance and physician preference: Limited awareness and usage outside of fibromyalgia restricts growth. Physicians favor drugs with broader evidence basis or multi-indication approval.

• Pricing and reimbursement policies: Marginal reimbursement rates in some markets suppress sales growth.

How do patent protections and generic competition influence financial trajectory?

Milnacipran was under patent protection until around 2017. Once expired, generic versions dramatically reduced pricing, decreasing revenue substantially.

As of 2022, multiple generics are available in key markets, leading to a 70-80% reduction in average price per prescription. This trend losses annual revenue estimates by approximately $50 million in the U.S. alone over five years.

What are the strategic opportunities and risks?

Opportunities:

• Development of new indications, such as major depressive disorder or neuropathic pain.
• Formulation enhancements, including extended-release versions.
• Market expansion in countries with limited current access.

Risks:

• Limited patent longevity detection.
• High competition from existing SNRIs with broader approval bases.
• Shifts towards non-pharmacologic treatments for fibromyalgia reducing demand.

What is the financial outlook?

Forecasts suggest a significant revenue decline over the next five years due to generic competition and narrow indication scope. Anticipated revenues in 2023 are approximately $10 million globally, with projections falling below $5 million by 2025 unless new indications or formulations are secured.

Investments into R&D for new indications could stabilize or boost revenues but involve high costs and uncertain success. Parallels with duloxetine show limited prospects without regulatory and formulary expansions.

Key Takeaways

• Milnacipran Hydrochloride primarily treats fibromyalgia, with limited broader applicability.
• Sales peaked around 2013; declines follow patent expiry and generics.
• The drug faces fierce competition from multiple generics and other SNRI drugs.
• Revenue prospects depend on expanding indications, formulations, or market access.
• Current financial trajectory points to continued decline unless strategic innovations are implemented.

FAQs

1. What markets are most significant for Milnacipran Hydrochloride?
The U.S. and Japan account for the majority of sales, with limited distribution in Europe.

2. How do patents affect its market exclusivity?
Patent expiry around 2017 allowed generics, leading to substantial price and revenue declines.

3. Can new indications revive its sales?
Potentially, but no recent filings or clinical trials are documented. Approval for additional uses remains uncertain.

4. How does Milnacipran compare to duloxetine?
Duloxetine has broader FDA indications, including depression and anxiety, resulting in higher sales and market penetration.

5. What strategic moves could influence its future market value?
Developing new indications, improving drug formulations, and expanding international access could impact sales positively.

---

References

[1] IMS Health. (2014). US Prescription Market Data.
[2] Mitsubishi Tanabe Pharma. (2022). Savella Annual Report.
[3] Food and Drug Administration. (2009). FDA Approval Letter for Milnacipran.
[4] European Medicines Agency. (2011). Summary of Product Characteristics for Milnacipran.
[5] MarketWatch. (2022). SNRI Market Trends.